BRUKINSA is a BTK inhibitor that was
designed to completely block BTK
BRUKINSA® (zanubrutinib) has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The signiﬁcance of completely blocking BTK on treatment responses has not been established.
BRUKINSA is a prescription medicine used to treat adults with:
- Waldenström's macroglobulinemia (WM).
- Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
- Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
BRUKINSA was approved for MCL and MZL based on response rate. There are ongoing evaluations to confirm clinical benefit for these uses. It is not known if BRUKINSA is safe and effective in children.